1. Pink Sheet
  2. >>Legislation

Speaking Up For Orphan Drugs

 
• By Michael McCaughan

A colloquy between Sen. Orrin Hatch and HHS Secretary Nominee Tom Price offered a timely rebuttal to a strangely one-sided investigative piece on the Orphan Drug law by Kaiser Health News and NPR.

The Senate Health, Education, Labor & Pensions Committee hearing on the nomination of Tom Price as HHS Secretary demonstrated that Price is a master of the fine art of dodging difficult questions without dismissing them.

Price was of course asked about the big topics of the day – repealing the Affordable Care Act being the biggest, but plans to address drug pricing being the more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.